The Single Shield Prize calls for innovative solutions enabling the development of vaccines that could provide protection in only one visit.
The Single Shield Prize is a competition to advance single-administration vaccine platforms for pandemic influenza A(H5N1). Vaccine developers and researchers, biotech companies, and other innovators can compete for more than $80 million in awards while gaining access to technical support and opportunities to connect with collaborators, industry partners, and potential investors. Eligible entrants are invited to submit a concept paper by January 15, 2027.
The total prize pool is $32 million. Up to eight winners will have the opportunity to receive up to $4 million each.
The total prize pool is $32 million. Up to four winners will have the opportunity to receive up to $8 million each.
Award details for Stage 2 will be released prior to the launch of Stage 2, anticipated mid-2029.
The Single Shield Prize is accepting Concept Stage submissions until January 15, 2027. To submit, entrants must first complete a Declaration of Intent (DOI). DOIs will be reviewed on a rolling basis until January 5, 2027.
The Single Shield Prize expects to award more than $80 million across three stages to advance single-administration vaccine platforms for pandemic influenza A(H5N1).
Teaming collaborations between diverse innovators are encouraged to help advance the development of a single-administration A(H5N1) vaccine. Those interested in teaming can share a participant profile to facilitate team formation.